Imatinib mesylate therapy for polycythemia vera: Final result of a phase II study initiated in 2001

International Journal of Hematology

Volumn 90, Issue 1, 2009, Pages 58-63

  Nussenzveig, Roberto H ^a,d   Cortes, Jorge ^a   Sever, Matjaz ^a   Quintás Cardama, Alfonso ^a   Ault, Pat ^a   Manshouri, Taghi ^a   Bueso Ramos, Carlos ^b   Prchal, Josef T ^c   Kantarjian, Hagop ^a   Verstovsek, Srdan ^a  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^b UNIVERSITY OF TEXAS   (United States)

^c UNIVERSITY OF UTAH SCHOOL OF MEDICINE   (United States)

^d ARUP LABORATORIES   (United States)

Author keywords

Imatinib mesylate; JAK2 mutation; Polycythemia vera

Indexed keywords

ANAGRELIDE; HYDROXYUREA; IMATINIB; JANUS KINASE 2;

ADULT; AGED; ARTICLE; BLEEDING; BLOOD CLOTTING DISORDER; BLOOD TOXICITY; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED STUDY; DIARRHEA; DRUG DOSE INCREASE; DRUG DOSE REDUCTION; DRUG EFFECT; DRUG TOLERABILITY; DRUG WITHDRAWAL; FEMALE; GENE MUTATION; HUMAN; MALE; MUSCLE CRAMP; PHASE 2 CLINICAL TRIAL; PHLEBOTOMY; POLYCYTHEMIA VERA; TREATMENT DURATION; TREATMENT RESPONSE; UNSPECIFIED SIDE EFFECT;

ADULT; AGED; AGED, 80 AND OVER; AMINO ACID SUBSTITUTION; FEMALE; HUMANS; JANUS KINASE 2; MALE; MIDDLE AGED; MUTATION, MISSENSE; PIPERAZINES; POLYCYTHEMIA VERA; PROTEIN KINASE INHIBITORS; PROTO-ONCOGENE PROTEINS C-ABL; PROTO-ONCOGENE PROTEINS C-KIT; PYRIMIDINES; RECEPTORS, PLATELET-DERIVED GROWTH FACTOR; TIME FACTORS;

EID: 70350575320     PISSN: 09255710     EISSN: None     Source Type: Journal    
DOI: 10.1007/s12185-009-0345-y     Document Type: Article

References (27)

1. JF Prchal JT Prchal 1999 Molecular basis for polycythemia Curr Opin Hematol 6 2 100 109 10.1097/00062752-199903000-00008 10088640 10.1097/00062752-199903000-00008 1:STN:280:DyaK1M7os1Gjsw%3D%3D (Pubitemid 29342524)
2. JF Prchal AA Axelrad 1974 Letter: bone-marrow responses in polycythemia vera N Engl J Med 290 24 1382 4827655 1:STN:280:DyaE2c7mtFOgtw%3D%3D
3. BJ Druker, et al. 2001 Activity of a specific inhibitor of the BCR-ABL tyrosine kinase in the blast crisis of chronic myeloid leukemia and acute lymphoblastic leukemia with the Philadelphia chromosome N Engl J Med 344 14 1038 1042 10.1056/NEJM200104053441402 11287973 10.1056/NEJM200104053441402 1:CAS:528:DC%2BD3MXivFGnu7o%3D (Pubitemid 32267973)
4. J Cortes H Kantarjian 2004 Beyond chronic myelogenous leukemia: potential role for imatinib in Philadelphia-negative myeloproliferative disorders Cancer 100 10 2064 2078 10.1002/cncr.20211 15139047 10.1002/cncr.20211 1:CAS:528:DC%2BD2cXksF2rsr8%3D (Pubitemid 38580323)
5. L Oehler, et al. 2003 Imatinib mesylate inhibits autonomous erythropoiesis in patients with polycythemia vera in vitro Blood 102 6 2240 2242 10.1182/blood-2003-03-0676 12763928 10.1182/blood-2003-03-0676 1:CAS:528:DC%2BD3sXntlKrsLs%3D (Pubitemid 37122405)
6. A Gaikwad, et al. 2007 Imatinib effect on growth and signal transduction in polycythemia vera Exp Hematol 35 6 931 938 10.1016/j.exphem.2007.03.012 17533047 10.1016/j.exphem.2007.03.012 1:CAS:528:DC%2BD2sXlvFamurs%3D (Pubitemid 46802991)
7. CM Jones TM Dickinson 2003 Polycythemia vera responds to imatinib mesylate Am J Med Sci 325 3 149 152 10.1097/00000441-200303000-00007 12640290 10.1097/00000441-200303000-00007 (Pubitemid 36348620)
8. RT Silver 2003 Imatinib mesylate (Gleevec(TM)) reduces phlebotomy requirements in polycythemia vera Leukemia 17 6 1186 1187 10.1038/sj.leu.2402938 12764388 10.1038/sj.leu.2402938 1:STN:280:DC%2BD3s3ktFOitA%3D%3D (Pubitemid 36722252)
9. RT Silver 2005 Treatment of polycythemia vera with recombinant interferon alpha (rIFNalpha) or imatinib mesylate Curr Hematol Rep 4 3 235 237 15865878 1:CAS:528:DC%2BD28XktVeiug%3D%3D
10. JL Spivak RT Silver 2004 Imatinib mesylate in polycythemia vera Blood 103 8 3241 10.1182/blood-2003-12-4248 15070710 10.1182/blood-2003-12-4248 1:CAS:528:DC%2BD2cXjsVagsbk%3D author reply 3241-3242 (Pubitemid 38451706)
11. EJ Baxter, et al. 2005 Acquired mutation of the tyrosine kinase JAK2 in human myeloproliferative disorders Lancet 365 9464 1054 1061 15781101 1:CAS:528:DC%2BD2MXisFGrs7g%3D
12. C James, et al. 2005 A unique clonal JAK2 mutation leading to constitutive signalling causes polycythaemia vera Nature 434 7037 1144 1148 10.1038/nature03546 15793561 10.1038/nature03546 1:CAS:528:DC%2BD2MXjsF2ltbk%3D (Pubitemid 40663494)
13. R Kralovics, et al. 2005 A gain-of-function mutation of JAK2 in myeloproliferative disorders N Engl J Med 352 17 1779 1790 10.1056/NEJMoa051113 15858187 10.1056/NEJMoa051113 1:CAS:528:DC%2BD2MXjsFyhsLw%3D (Pubitemid 40570926)
14. RL Levine, et al. 2005 Activating mutation in the tyrosine kinase JAK2 in polycythemia vera, essential thrombocythemia, and myeloid metaplasia with myelofibrosis Cancer Cell 7 4 387 397 10.1016/j.ccr.2005.03.023 15837627 10.1016/j.ccr.2005.03.023 1:CAS:528:DC%2BD2MXjvFSku7o%3D (Pubitemid 40544655)
15. Lacout C, et al. JAK2V617F expression in murine hematopoietic cells leads to MPD mimicking human PV with secondary myelofibrosis. Blood. 2006;108(5):1652-60.
16. AV Jones, et al. 2005 Widespread occurrence of the JAK2 V617F mutation in chronic myeloproliferative disorders Blood 106 6 2162 2168 10.1182/blood-2005- 03-1320 15920007 10.1182/blood-2005-03-1320 1:CAS:528:DC%2BD2MXhtVWksLvF (Pubitemid 41291734)
17. S Verstovsek, et al. 2006 JAK2V617F mutational frequency in polycythemia vera: 100%, >90%, less? Leukemia 20 11 2067 10.1038/sj.leu.2404379 16990780 10.1038/sj.leu.2404379 1:STN:280:DC%2BD28nivFGisQ%3D%3D (Pubitemid 44614909)
18. RH Nussenzweig, et al. 2007 Polycythemia vera is not initiated by JAK2V617F mutation Exp Hematol 35 1 32 38
19. BJ Druker, et al. 1996 Effects of a selective inhibitor of the Abl tyrosine kinase on the growth of Bcr-Abl positive cells Nat Med 2 5 561 566 10.1038/nm0596-561 8616716 10.1038/nm0596-561 1:CAS:528:DyaK28Xislyhs70%3D (Pubitemid 26151518)
20. R Zhao, et al. 2005 Identification of an acquired JAK2 mutation in polycythemia vera J Biol Chem 280 24 22788 22792 10.1074/jbc.C500138200 15863514 10.1074/jbc.C500138200 1:CAS:528:DC%2BD2MXltVyhtro%3D (Pubitemid 40853184)
21. SR Weiler, et al. 1996 JAK2 is associated with the c-kit proto-oncogene product and is phosphorylated in response to stem cell factor Blood 87 9 3688 3693 8611693 1:CAS:528:DyaK28Xis1Sjtro%3D
22. A Fontalba, et al. 2006 Identification of c-Kit gene mutations in patients with polycythemia vera Leuk Res 30 10 1325 1326 10.1016/j.leukres.2005. 12.020 16460801 10.1016/j.leukres.2005.12.020 1:CAS:528:DC%2BD28XotlKitrk%3D (Pubitemid 44240452)
23. VM Zaleskas, et al. 2006 Molecular pathogenesis and therapy of polycythemia induced in mice by JAK2 V617F PLoS One 1 e18 10.1371/journal.pone. 0000018 17183644 10.1371/journal.pone.0000018
24. R Silver S Fruchtman E Feldman, et al. 2004 Imatinib mesylate (Gleevec) is effective in the treatment of polycythemia vera: a multi-institutional clinical trial Blood 104 11 189a
25. CM Jones TM Dickinson A Salvado 2008 Phase II open label trial of imatinib in polycythemia rubra vera Int J Hematol 88 5 489 494 10.1007/s12185-008-0193-1 19009241 10.1007/s12185-008-0193-1 1:CAS:528:DC%2BD1MXkvVamtQ%3D%3D
26. AV Jones, et al. 2006 Minimal molecular response in polycythemia vera patients treated with imatinib or interferon alpha Blood 107 8 3339 3341 10.1182/blood-2005-09-3917 16352805 10.1182/blood-2005-09-3917 1:CAS:528:DC%2BD28Xjs1OksL0%3D
27. Quintas-Cardama AC, J, Kantarjian H. Practical management of toxicities associated with tyrosine kinase inhibitors in chronic myeloid leukemia. Clin Lymphoma Myeloma. 2008;8(Suppl. 3):S82-8. doi: 10.3816/CLM.2008.s.003.